An update on the pharmacological treatment of obsessive-compulsive disorder
- PMID: 17376013
- DOI: 10.1517/14656566.8.5.563
An update on the pharmacological treatment of obsessive-compulsive disorder
Abstract
The purpose of this article is to introduce the reader to an updated evidence-based drug treatment algorithm to be employed in patients with obsessive-compulsive disorder (OCD). Relevant studies were identified through a comprehensive review and classified according to the type of patients enrolled, the quality of the study design and the invasiveness, availability and complexity of the therapeutic approach. When ineffective, therapeutic trials with first-line strategies (such as the selective serotonin re-uptake inhibitors [SSRIs] and venlafaxine) should be followed by treatment approaches such as clomipramine, augmentation with antipsychotics or pindolol, SSRI megadoses or cognitive behavioral therapy. These therapeutic strategies are expected to help most patients with OCD. Additional approaches include intravenous clomipramine, oral morphine, 'heroic drug strategies', deep brain stimulation and functional neurosurgery. Independent studies are urgently needed to help identify the most promising drug treatment sequences for OCD.
Similar articles
-
Pharmacological management of treatment-resistant obsessive-compulsive disorder.CNS Drugs. 2011 Jul;25(7):585-96. doi: 10.2165/11587860-000000000-00000. CNS Drugs. 2011. PMID: 21699270 Review.
-
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.Braz J Psychiatry. 2023 May 11;45(2):146-161. doi: 10.47626/1516-4446-2022-2891. Braz J Psychiatry. 2023. PMID: 36749887 Free PMC article.
-
A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645. Curr Med Chem. 2018. PMID: 29278206
-
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).Curr Neuropharmacol. 2019;17(8):710-736. doi: 10.2174/1570159X16666180813155017. Curr Neuropharmacol. 2019. PMID: 30101713 Free PMC article. Review.
-
Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.J Affect Disord. 2016 Aug;200:89-96. doi: 10.1016/j.jad.2016.04.035. Epub 2016 Apr 21. J Affect Disord. 2016. PMID: 27130958
Cited by
-
Management of obsessive-compulsive disorder with fluvoxamine extended release.Neuropsychiatr Dis Treat. 2009;5:301-8. doi: 10.2147/ndt.s3301. Epub 2009 Jun 10. Neuropsychiatr Dis Treat. 2009. PMID: 19557140 Free PMC article.
-
The Therapeutic Effect of Electroconvulsive Therapy in Patients With Obsessive-compulsive Disorder: A Quasi-experimental Study.Basic Clin Neurosci. 2023 Jan-Feb;14(1):19-30. doi: 10.32598/bcn.2022.3524.1. Epub 2023 Jan 1. Basic Clin Neurosci. 2023. PMID: 37346874 Free PMC article.
-
Attenuation of compulsive-like behavior by fluvoxamine in a non-induced mouse model of obsessive-compulsive disorder.Behav Pharmacol. 2018 Jun;29(4):299-305. doi: 10.1097/FBP.0000000000000348. Behav Pharmacol. 2018. PMID: 29035919 Free PMC article.
-
Specificity of fear and disgust experienced during traumatic interpersonal victimization in predicting posttraumatic stress and contamination-based obsessive-compulsive symptoms.J Anxiety Disord. 2012 Jun;26(5):590-8. doi: 10.1016/j.janxdis.2012.03.001. Epub 2012 Mar 14. J Anxiety Disord. 2012. PMID: 22465821 Free PMC article.
-
Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.Child Psychiatry Hum Dev. 2017 Oct;48(5):699-704. doi: 10.1007/s10578-016-0694-8. Child Psychiatry Hum Dev. 2017. PMID: 27812841
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical